LBT-3627
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) that can change the behavior of immune cells so they protect dopamine-producing cells rather than attacking them.[1] The drug has the potential to be administered orally. The drug may one day help those with Parkinson's disease.[2]
Function
LBT-3627 specifically targets the VIP2 receptor, unlike VIP.[3] The drug also affects microglia.[1] In addition, LBT-3627 is more durable in the body compared to VIP.[4]
History and development
Scientists at the University of Nebraska Medical Center and Longevity Biotech, Inc. first demonstrated the use of the drug in mouse models.[2][4]
A phase I trial for humans is planned for 2017.[4]
References
- 1 2 Paddock, Catharine (December 17, 2015). "New drug that protects dopamine cells raises treatment hope for Parkinson's". Medical News Today. Retrieved December 18, 2015.
- 1 2 "Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies". PR Newswire. December 16, 2015. Retrieved December 21, 2015.
- ↑ Azevedo, Margarida (December 21, 2015). "New Drug Candidate Shows Promise in Animal Model of Parkinson's". Parkinson's News Today. Retrieved December 21, 2015.
- 1 2 3 Block, Jonathan (December 17, 2015). "Drug That Protects Dopamine Cells Eyed as Parkinson's Treatment". Phychiatry Advisor. Retrieved December 21, 2015.
| Dopaminergics |
| ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticholinergics | |||||||||||||||||||
| Others | |||||||||||||||||||
| |||||||||||||||||||
This article is issued from Wikipedia - version of the 12/24/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.